Abstract
Risk factors for the development of vancomycin-associated acute kidney injury (AKI) have been evaluated in both pediatric and adult populations; however, no previous studies exist evaluating this in the critically ill adolescent and young adult patients. Identify the incidence of AKI and examine risk factors for the development of AKI in critically ill adolescents and young adults on vancomycin. This retrospective review evaluated the incidence of AKI in patients 15 to 25 years of age who received vancomycin, while admitted to an intensive care unit. Acute kidney injury in this population was defined as an increase in serum creatinine by 0.5 mg/dL or 50% from baseline. Patients who developed AKI were evaluated for specific risk factors compared to those who did not develop AKI. A total of 50 patients (20 developed AKI) were included in the study. There was no difference in vancomycin daily dose or duration of vancomycin therapy. Maximum vancomycin trough (31.15 mg/dL vs 12.5 mg/dL, P = .006), percentage of patients with concurrent nephrotoxic medication (95% vs 60%, P = .012) and concurrent vasopressor (55% vs 23%, P = .029) were higher in those who developed AKI. Percentage of patients who underwent a procedure while on vancom...Continue Reading
References
Apr 1, 1990·The Journal of Antimicrobial Chemotherapy·M J RybakP H Chandrasekar
Apr 11, 2000·Journal of Critical Care·M L GloverJ Wolfsdorf
Sep 19, 2003·The New England Journal of Medicine·Gregory L KearnsRalph E Kauffman
Aug 23, 2005·Toxicology·Faruk OktemEfkan Uz
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Donald P Levine
Aug 19, 2007·Clinical Therapeutics·Meghan N JeffresMarin H Kollef
Apr 11, 2008·Critical Care Medicine·Rinaldo BellomoClive May
Oct 22, 2008·Toxicological Sciences : an Official Journal of the Society of Toxicology·Christine DieterichHanna H Ng
Dec 25, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael RybakDonald P Levine
Oct 5, 2010·The Journal of Pediatrics·Susan McKamyJennifer Le
Jan 11, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Catherine LiuHenry F Chambers
Sep 13, 2011·Annals of Intensive Care·Mike S StrundenDaniel A Reuter
Jan 31, 2012·Clinical Therapeutics·Ennie L CanoUNKNOWN Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Study Group
Mar 14, 2012·European Journal of Clinical Pharmacology·Sepideh ElyasiAmirhooshang Mohammadpour
Oct 18, 2012·The Annals of Pharmacotherapy·Amy HoreyArun Mattappallil
Nov 21, 2012·Antimicrobial Agents and Chemotherapy·S J van HalT P Lodise
Mar 26, 2013·Pharmacotherapy·Balagangadhar R TotapallyAndre Raszynski
May 24, 2014·Pharmacotherapy·Lindsey D Burgess, Richard H Drew
Jun 18, 2014·Congenital Heart Disease·Brady S MoffettRonald Bronicki
Aug 2, 2014·Critical Care Medicine·Timothy P HanrahanJason A Roberts
Jul 15, 2015·The Annals of Pharmacotherapy·Chad A KnodererAmy C Wilson
Aug 28, 2015·Anaesthesia and Intensive Care·T P HanrahanA Udy
Jun 14, 2016·Journal of Clinical Pharmacology·Shankar LankeCatherine M Sherwin
Jun 14, 2016·Therapeutic Advances in Endocrinology and Metabolism·Oluwatoyin Bamgbola
Citations
May 18, 2020·The Journal of Antimicrobial Chemotherapy·Ioannis BellosVasilios Pergialiotis
Oct 28, 2019·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Amanda M Uber, Scott M Sutherland
Mar 8, 2020·Pediatrics International : Official Journal of the Japan Pediatric Society·Nuntawan PiyaphaneeAchra Sumboonnanonda